Edwards Lifesciences is the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. Driven by a passion to help patients, the company collaborates with the world’s leading clinicians and researchers to address unmet healthcare needs, working to improve patient outcomes and enhance lives.
Edwards monitoring solutions measure cardiovascular performance and include products such as the Swan Ganz Pulmonary Catheter, the FloTrac system and the noninvasive ClearSight system.
Edwards recently released the first predictive monitoring parameter called the Hypotension Prediction Index (HPI). HPI offers the ability to detect and respond to developing hypotension by recognizing trends and providing alerts before they impact patients.